**Supplementary File**

**Molecular target prediction and docking of anti-thrombosis compounds and its activation on tissue-plasminogen activator to treat stroke**

Bader Alshehri1, Rajendran Vijayakuamar2, Subramanian Senthilkumar3, Ahmed Ismail4, Ahmed Abdelhadi1,5, Ranjay K. Choudhary1, Kamal S. Albenasy1, Saeed Banawas1, Mohammed A Alaidarous1, Palanisamy Manikandan1,6,\*

1Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia, Kingdom of Saudi Arabia

2Department of Biology, College of Science, Majmaah University, Majmaah 11952, Saudi Arabia, Kingdom of Saudi Arabia

3Department of Medicine, College of Medicine and Health Science, Jigjiga university, Ethiopia.

4Department of Public health, College of Applied Medical Sciences, Majmaah University, Majmaah 11952, Saudi Arabia, Kingdom of Saudi Arabia

5Botany and Microbiology Department, Faculty of Science, Al-Azhar University, Assiut Branch, Egypt

6Greenlink Analytical and Research Laboratory India Private Limited, Coimbatore 641 014, India

Corresponding Author:

Palanisamy Manikandan

Email: [m.palanisamy@mu.edu.sa](mailto:m.palanisamy@mu.edu.sa)

**Table S1.** ADMET properties of the selected ligands

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Properties | Caesalpinine C | Vanillylamine | Caesalpinine A | SABINENE | Terpinen-4-Ol | Dihydrocapsaicin | Dihydrocarveol | BETA-PINENE | CAMPHENE | 3-Carene |
| Pgp - inhibitor# | 0.901 | 0 | 0.118 | 0 | 0.001 | 0.007 | 0 | 0.001 | 0 | 0 |
| Pgp -substrate# | 0.328 | 0.429 | 0.003 | 0 | 0.002 | 0.016 | 0.004 | 0 | 0 | 0 |
| Human Intestinal Absorbtion# | 0.374 | 0.009 | 0.605 | 0.003 | 0.004 | 0.003 | 0.011 | 0.003 | 0.003 | 0.003 |
| Caco-2## | -5.281 | -4.53 | -5.361 | -4.4 | -4.217 | -4.541 | -4.34 | -4.46 | -4.463 | -4.307 |
| BBB# | 0.64 | 0.057 | 0.452 | 0.976 | 0.931 | 0.911 | 0.973 | 0.986 | 0.975 | 0.804 |
| PPB \* | 91.34% | 16.54% | 51.23% | 69.45% | 85.34% | 96.22% | 49.59% | 64.33% | 67.76% | 91.52% |
| CYP1A2- inhibitor# | 0.093 | 0.622 | 0.023 | 0.497 | 0.274 | 0.759 | 0.134 | 0.296 | 0.601 | 0.706 |
| CYP1A2- substrate# | 0.212 | 0.758 | 0.074 | 0.384 | 0.258 | 0.903 | 0.685 | 0.352 | 0.859 | 0.324 |
| CYP2C19- inhibitor# | 0.328 | 0.101 | 0.179 | 0.123 | 0.112 | 0.902 | 0.024 | 0.163 | 0.193 | 0.339 |
| CYP2C19- substrate# | 0.532 | 0.559 | 0.695 | 0.9 | 0.846 | 0.779 | 0.839 | 0.825 | 0.879 | 0.839 |
| CYP2C9- inhibitor# | 0.104 | 0.025 | 0.071 | 0.113 | 0.058 | 0.722 | 0.024 | 0.321 | 0.171 | 0.275 |
| CYP2C9- substrate# | 0.127 | 0.814 | 0.065 | 0.398 | 0.704 | 0.94 | 0.804 | 0.794 | 0.852 | 0.77 |
| CYP2D6- inhibitor# | 0.837 | 0.296 | 0.697 | 0.045 | 0.025 | 0.836 | 0.003 | 0.009 | 0.016 | 0.013 |
| CYP2D6- substrate# | 0.67 | 0.914 | 0.528 | 0.744 | 0.278 | 0.859 | 0.879 | 0.859 | 0.896 | 0.448 |
| CYP3A4- inhibitor# | 0.749 | 0.069 | 0.678 | 0.108 | 0.04 | 0.879 | 0.02 | 0.026 | 0.051 | 0.045 |
| CYP3A4- substrate# | 0.465 | 0.202 | 0.68 | 0.273 | 0.261 | 0.222 | 0.296 | 0.252 | 0.289 | 0.23 |
| Clearance \*\* | 3.856 | 12.017 | 3.913 | 11.198 | 14.345 | 10.66 | 12.601 | 10.097 | 9.346 | 16.061 |
| T 1/2# | 0.588 | 0.895 | 0.197 | 0.194 | 0.447 | 0.856 | 0.367 | 0.107 | 0.077 | 0.132 |
| hERG# | 0.441 | 0.058 | 0.222 | 0.009 | 0.017 | 0.122 | 0.027 | 0.005 | 0.015 | 0.01 |
| DILI# | 0.033 | 0.109 | 0.027 | 0.155 | 0.05 | 0.067 | 0.045 | 0.051 | 0.104 | 0.049 |
| Ames# | 0.021 | 0.069 | 0.012 | 0.029 | 0.007 | 0.051 | 0.026 | 0.005 | 0.004 | 0.004 |
| Carcinogenicity# | 0.057 | 0.151 | 0.028 | 0.305 | 0.688 | 0.04 | 0.449 | 0.042 | 0.194 | 0.147 |
| Rat Oral Acute Toxicity# | 0.538 | 0.881 | 0.15 | 0.088 | 0.025 | 0.036 | 0.039 | 0.028 | 0.025 | 0.035 |
| Skin Sensitivity# | 0.937 | 0.767 | 0.076 | 0.059 | 0.456 | 0.877 | 0.146 | 0.068 | 0.267 | 0.785 |
| Respiratory toxicity# | 0.756 | 0.932 | 0.08 | 0.305 | 0.024 | 0.06 | 0.718 | 0.933 | 0.886 | 0.266 |

#All values are the probability of being 1.

##optimal values – having > -5.15 log unit.

\*Plasma Protein Binding - <90% is optimal.

\*\*Clearance - <5 is low and >15 is high

**Table S2.** Biological activity of ligands predicted using PASS server.

|  |  |  |  |
| --- | --- | --- | --- |
| **Ligand** | **Pa** | **Pi** | **Activity** |
| Caesalpinine C | 0.791 | 0.004 | Antihypoxic |
| 0.764 | 0.011 | Nicotinic alpha4beta4 receptor agonist |
| 0.756 | 0.026 | Nootropic |
|  | 0.396 | 0.158 | Fibrinolytic |
| Vanillylamine | 0.899 | 0.008 | Aspulvinonedimethylallyltransferase inhibitor |
| 0.879 | 0.005 | Feruloyl esterase inhibitor |
| 0.841 | 0.005 | JAK2 expression inhibitor |
| 0.396 | 0.158 | Fibrinolytic |
| Caesalpinine A | 0.809 | 0.005 | Antidyskinetic |
| 0.802 | 0.016 | Gluconate 2-dehydrogenase (acceptor) inhibitor |
| 0.765 | 0.015 | Nicotinic alpha2beta2 receptor antagonist |
| Sabinene | 0.947 | 0.003 | Antieczematic |
| 0.891 | 0.005 | Antineoplastic |
| 0.853 | 0.005 | Antiinflammatory |
| Terpinen-4-Ol | 0.871 | 0.019 | CYP2C12 substrate |
| 0.838 | 0.011 | Antieczematic |
| 0.829 | 0.003 | Carminative |
| 0.729 | 0.014 | Fibrinolytic |
| Dihydrocapsaicin | 0.821 | 0.016 | Acrocylindropepsin inhibitor |
| 0.821 | 0.016 | Chymosin inhibitor |
| 0.821 | 0.016 | Saccharopepsin inhibitor |
| 0.675 | 0.033 | Fibrinolytic |
| Dihydrocarveol | 0.976 | 0 | Carminative |
| 0.912 | 0.001 | Alpha-pinene-oxide decyclase inhibitor |
| 0.912 | 0.004 | Antieczematic |
| Beta-pinene | 0.902 | 0.005 | Antieczematic |
| 0.857 | 0.013 | Testosterone 17beta-dehydrogenase (NADP+) inhibitor |
| 0.846 | 0.011 | CYP2J substrate |
| 0.758 | 0.005 | Cardiovascular analeptic |
| Camphene | 0.882 | 0.006 | Antieczematic |
| 0.873 | 0.01 | Testosterone 17beta-dehydrogenase (NADP+) inhibitor |
| 0.829 | 0.014 | CYP2J substrate |
| 0.816 | 0.004 | Cardiovascular analeptic |
| 3-Carene | 0.878 | 0.009 | Testosterone 17beta-dehydrogenase (NADP+) inhibitor |
| 0.86 | 0.009 | CYP2J substrate |
| 0.863 | 0.021 | CYP2C12 substrate |
| 0.815 | 0.005 | Antidyskinetic |
| 0.646 | 0.048 | Fibrinolytic |